Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors

Posted on January 6, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of Pam Prior, CPA, to its Board … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building AI-driven Ovarian Cancer Model to Predict Tumor Drug Response, Patient Outcome

Posted on December 30, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), through its subsidiary Helomics, is sequencing ovarian cancers as part of a CancerQuest 2020 project, building the largest ovarian multi-omic database in the world. An article discussing the company reads, “As part of its CancerQuest 2020 … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Revolutionary Technology Enables Faster, More Accurate Tumor Identification

Posted on December 26, 2019 by MissionIR

Data and artificial-intelligence (“AI”) driven, discovery-services company Predictive Oncology’s (NASDAQ: POAI) subsidiary TumorGenesis is developing quicker, less costly and more precise Patient Derived Xenograft (“PDx”) cancer models that better mimic the patient’s tumor. An article discussing the company reads, “TumorGenesis … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Extension of Secured Promissory Note

Posted on December 17, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the extension of its secured promissory note. According to the … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Notes Indications of Interest in Medical Division; Regains Nasdaq Price Compliance

Posted on December 16, 2019 by MissionIR

Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System POAI also regained compliance with Nasdaq’s minimum bid price requirement Predictive Oncology … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Reports 58% Revenue Increase; Notes Business Highlights for Q3 2019

Posted on December 13, 2019 by MissionIR

POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018 Company reports records sales of proprietary systems, supplies Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future Predictive Oncology Inc. (NASDAQ: POAI), an artificial … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection

Posted on December 12, 2019 by MissionIR

POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world Company’s work designed to speed development of new drugs, provide therapeutic choices Helomics recently signed collaborative agreement with UPMC-Magee to establish … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Updates on Commercialization of Cancer Quest 2020 Initiative

Posted on December 9, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of its CancerQuest 2020 initiative. According … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Tech Primed to Play Key Role in Cancer Drug Development Efforts

Posted on December 5, 2019 by MissionIR

Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes There’s an … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Multiple Indications of Interest for Skyline Medical Division

Posted on December 5, 2019 by MissionIR

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its receipt of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment